In this article:
- Company Overview
- Stock Performance
- Market Position and Sector
- Governance and Leadership
- Key Financial Data
- FAQ
- Conclusion
- Disclaimer
- Official Source
Company Overview
Senseonics Holdings, Inc. is a medical technology company specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes. Its flagship products, the Eversense and Eversense XL, integrate implantable sensors under the skin, a rechargeable smart transmitter, and a mobile application for real-time glucose monitoring over extended durations of up to six months. The company operates across the United States, Europe, the Middle East, and Africa.
Founded in 1996 and headquartered in Germantown, Maryland, Senseonics leverages partnerships with distributors and strategic fulfillment collaborators to reach both healthcare providers and patients. A notable collaboration exists with the University Hospitals Accountable Care Organization.
Stock Performance
As of the latest market update, the SENS stock is trading at USD 0.4619. This represents a decrease of USD 0.0075 or approximately -1.60%. The current price sits within its 52-week range of USD 0.25 to USD 1.40, showing volatility characteristic of small-cap healthcare equities.
Trading volume has reached 11,225,041 shares, significantly above the average volume of 7,211,593 shares. Higher-than-average trading volume can indicate increased investor interest, heightened speculation, or responses to recent announcements. Market capitalization is currently at USD 376,301,112, positioning Senseonics within the micro to small-cap segment where price fluctuations can be more pronounced.
The company does not currently pay a dividend, which indicates earnings are likely reinvested into operations and product development rather than distributed to shareholders.
Market Position and Sector
Senseonics operates within the medical devices industry, specifically targeting diabetes management technology. The sector is heavily regulated, requiring stringent adherence to healthcare quality standards and regulatory approvals.
The healthcare sector in general, and medical devices in particular, benefit from consistent demand driven by chronic health conditions and technological innovation. However, competition from both established multinationals and emerging startups is significant.
Governance and Leadership
Under the leadership of CEO Timothy T. Goodnow, the company has focused on expanding its product adoption, emphasizing clinical performance and patient convenience. Corporate governance aligns with healthcare compliance obligations and investor transparency standards.
Full-time employee count stands at 117, reflecting a lean operational model that likely centers on research, development, strategic partnerships, and commercialization.
Key Financial Data
- Current Price: USD 0.4619
- Market Cap: USD 376,301,112
- 52-Week Range: USD 0.25 – USD 1.40
- Dividend: USD 0 (no payout)
- Volume: 11,225,041 shares
- Average Volume: 7,211,593 shares
These indicators provide insight into liquidity, valuation, and volatility. A low share price combined with higher trading volume can signal speculative interest or reaction to performance updates. Market capitalization gives context on company size and potential risk profile. Dividend policy reflects strategic allocation of earnings.
FAQ
- Does Senseonics Holdings pay dividends?
No, the company does not currently provide dividend payouts to shareholders. - On which exchange is SENS listed?
SENS trades on the New York Stock Exchange Arca (AMEX). - What are the identification codes for SENS?
ISIN: US81727U1051, CUSIP: 81727U105. - How many employees does the company have?
Senseonics Holdings employs 117 full-time staff. - When was the IPO date?
The company went public on December 22, 2015.
Conclusion
Senseonics Holdings, Inc. continues to navigate the competitive medical devices market with a focus on diabetes management solutions. The latest trading data reflects active investor engagement and price movement within a volatile range. For stakeholders, monitoring trading volume alongside product and regulatory updates remains essential.
Disclaimer
This article is for informational purposes only. It does not constitute investment, legal, or tax advice. Investors should conduct their own due diligence before making financial decisions.
Official Source
For full information about the company, see the link below.